Preferences and utilities for the symptoms of moderate to severe allergic asthma

European Journal of Health Economics

Volumn 9, Issue 3, 2008, Pages 275-284

  Lloyd, Andrew ^a   Doyle, Scott ^b   Dewilde, Sarah ^b   Turk, Florian ^c  

^a ICON PLC   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asthma; Preference; Utility; Valuation; Willingness to pay (WTP)

Indexed keywords

CORTICOSTEROID; OMALIZUMAB;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; COUGHING; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SYMPTOM; WHEEZING;

ADULT; ALLERGENS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHOICE BEHAVIOR; DECISION MAKING; FEMALE; GREAT BRITAIN; HUMANS; MALE; PAIN MEASUREMENT; PILOT PROJECTS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 46949104026     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0075-0     Document Type: Article

References (25)

1. Bennett, K., Torrance, G.: Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In: Spilker, B. (eds.) HRQL and Pharmacoeconomics in Clinical Trials, 2nd edn. Lippincott-Raven, Philadelphia, pp. 253-266 (1996)
2. Busse, W., Corren, J., Quentin Lanier, B., McAlary, M., Fowler-Taylor, A., Della Cioppa, van As A., Gupta, N.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108, 184-190 (2001)
3. Conner-Spady, B.L., et al.: A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant. 36(3), 251-259 (2005)
4. Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., Fowler-Taylor, A., Liu, J., Gupta, N.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 111, 278-284 (2003)
5. Furlong, W., Feeny, D., Torrance, G.W., Barr, R.D., Horsman, J.: Guide to design and development of health-state utility instrumentation. McMaster University CHEPA working paper series (1990)
6. Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. NIH Publication 02-3659 issued January 1995 (updated 2002, 2003; accessed 26 Oct 2004). Available at: http://www.ginasthma.com
7. Gold, M.R., Siegel, J.E., Russell, L.B., Weinstein, MC.: Cost-Effectiveness in Health and Medicine. Oxford University Press (1996)
8. Greene, W.H., Greene, L.K., Seaks, T.G.: Estimating the functional form of the independent variables in probit models. Appl. Econ. 27, 193-196 (1995)
9. Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hebert, J., Bousquet, J., Beech, K-M., Ramos, S., Canonica, G.W., Hedgecock, S., Fox, H., Blogg, M., Surrey, K.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Asthma 10, 1398 (2004)
10. Kind, P., Dolan, P., Gudex, C., Williams, A.: Variations in population health status: results from a United Kingdom national questionnaire survey. Br. Med. J. 316, 736-741 (1998)
11. Lloyd, A.J., McIntosh, E., Rabe, K., Williams, A.E.: Patient preferences for asthma therapy: a discrete choice experiment. Prim. Care Respir. J. (in press)
12. Lloyd, A.J., Price, D., Brown, R.: The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim. Care Respir. J. 16, 22-27 (2007)
13. Lloyd, A., Turk, F., Leighton, T., Canonica, G.W.: Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J. Med. Econ. 10(3), 285-296 (2007)
14. Louviere, J., Hensher, D., Swait, J.: Conjoint preference elicitation methods in the broader context of Random Utility Theory preference eliciation methods. In: Gustafson, A., Hermann, A., Huber, F. (eds.) Conjoint Measurement: Methods and Applications. Springer, Berlin, pp. 305-344 (2001)
15. Manski, C.F.: The structure of random utility models. Theory Decis. 8(229), 254 (1977)
16. Marshall. G.D. Jr, Sorkness, C.A.: IgE-blocking therapy for difficult-to-treat asthma: a brief review. Manag. Care 13(3), 45-50 (2004)
17. McFadden, E.R. Jr: Acute severe asthma. Am. J. Respir. Crit. Care Med. 168(7), 740-759 (2003)
18. Norum, J., et al.: Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur. J. Cancer 32A(9), 1510-1517 (1996)
19. Office of National Statistics, National Statistics website "Population of the United Kingdom: by ethnic group, April 2001". http://www.statistics.gov.uk/cci/nugget_print.asp?ID=764
20. Osman, L.M., McKenzie, L., Cairns, J., Friend, J.A.R., Godden, D.J., Legge, J.S., Douglas, J.G.: Patient weighting of importance of asthma symptoms. Thorax 56, 138-142 (2001)
21. Roe, B., Boyle, K.J., Teisl, M.F.: Using conjoint analysis to derive estimates of compensating variation. J. Environ. Econ. Manage. 31, 145-159 (1996)
22. Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien J., Fox, H., Thirlwell, J., Gupta, N.,Della Cioppa, G.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 18, 254-261 (2001)
23. Torrance, G.W.: Measurement of health state utilities for economic appraisal. J. Health Econ. 5(1), 1-30 (1986)
24. Torrance, G.W.: Preferences for health states: a review of measurement methods. Clin. Econ. Eval. Perinat. Dev. Med. 20, 37-45 (1982)
25. Torrance, G.W.: Utility approach to measuring health-related quality of life. J. Chronic Dis. 40(6), 593-600 (1987)